Bristol-Myers Squibb Co.

NYSE:BMY   3:59:57 PM EDT
+0.22 (+0.38%)

U.S. FDA Approves Bristol-Myers Squibb Co And bluebird bio Inc's Abecma

Published: 03/27/2021 04:26 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and Bluebird Bio’s Abecma (idecabtagene Vicleucel), the First Anti-bcma Car T Cell Therapy for Relapsed Or Refractory Multiple Myeloma.